# A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

> **NCT02042378** · PHASE2 · COMPLETED · sponsor: **pharmaand GmbH** · enrollment: 19 (actual)

## Conditions studied

- Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT02042378
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-04
- **Final completion:** 2016-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02042378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02042378, "A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02042378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*